Usher syndrome is recognized as the most frequent cause of hereditary deaf-blindness. Usher syndrome type I (USH1), the most severe form of the disease, is characterized by profound congenital sensorineural deafness, constant vestibular dysfunction, and retinitis pigmentosa of prepubertal onset. This form is genetically heterogeneous and five loci (USH1A-E) have been mapped thusfar. However, only the gene responsible for USH1B (which accounts for ∼75% of USH1 cases) has been characterized. It encodes a long-tailed unconventional myosin, myosin VIIA, with a predicted 2215 amino acid sequence. Primers covering the complete myosin VIIA coding sequence as well as the 3′ non coding sequence were designed, allowing direct sequence analysis of each of the 48 coding exons and flanking splice sites in seven patients affected by USH1. Four novel mutations were thereby identified. The possibility should now be considered of a sequencebased prenatal diagnosis in some of the families affected by this very severe form of Usher syndrome.
INTRODUCTION
Usher syndrome (1) associates congenital hearing loss and retinitis pigmentosa leading to blindness. Three clinical forms of this syndrome have been described, all of which are transmitted in an autosomal recessive manner. These forms vary in the severity of the hearing impairment, the presence or absence of vestibular dysfunction and the age of onset of retinitis pigmentosa. Usher syndrome type I (USH1) is the most severe form (2) , characterized by profound congenital hearing loss, constant vestibular dysfunction and retinitis pigmentosa of prepubertal onset; this form represents ∼50% of Usher syndrome cases. Five USH1 loci, USH1A-E, have been mapped so far (3) (4) (5) (6) (7) . Seventy-five per cent of USH1 cases in developed countries are accounted for by the USH1B locus (8, 9) .
In 1995, the gene encoding myosin VIIA, an unconventional myosin, was identified as responsible for USH1B (10, 11) through the analysis of five exons in seven USH1-affected families in which segregation analysis was consistent with the involvement of USH1B. Four mutations were identified in three families (10) ; two were nonsense mutations and the other two consisted of the same 6 bp deletion, deleting two amino acids implicated in the putative actin binding pocket (12) .
We have recently determined the entire coding sequence of the human myosin VIIA cDNA as well as the sequence of the 3′ and part of the 5′ untranslated regions (13) (GenBank accession number U39226). The deduced amino acid sequence predicts a 2215 amino acid polypeptide chain with a typical unconventional myosin structure, i.e. a motor head domain including the highly conserved ATP-and actin-binding sites, a neck domain with five IQ motifs (putative calmodulin binding sites) and a long tail domain of 1359 amino acids (see Fig. 1 ). The sequence of the 318 C-terminal amino acids shows homology to the ERM (Ezrin-Radixin-Moesin) domain of the band 4.1 superfamily members, a domain which has been shown to link with a protein component of the plasma membrane (14, 15) ; maximum homology was found with the ERM-domain of talin (GenBank accession number P26039), i.e. 26% amino acid identity and 48% similarity.
The myosin VIIA gene consists of 48 coding exons (10) . Here, we report further characterization of the exon-intron structure of the gene. In order to characterize the mutations in patients affected by Usher syndrome type IB, primers were designed to amplify each exon. These primers were used to analyze the gene in seven unrelated USH1 patients, leading to the characterization of four novel mutations in four patients.
RESULTS AND DISCUSSION

Structure of the human myosin VIIA gene
Two YACs (250B9 and 984B11) from a human genomic library (CEPH, Centre d'Etude du Polymorphisme Humain, Paris) were found to hybridize with the 5′ end and the 3′ end of the myosin *To whom correspondence should be addressed VIIA cDNA, respectively. These YACs were subcloned into a λ vector and a contig of nine λ clones was found to contain the complete coding portion as well as the 3′ and part of the 5′ untranslated regions of the myosin VIIA gene (10) . For each of the coding exons, intronic flanking sequences extending for a minimum of 150 bp were determined (see Materials and Methods). All of the exon-intron junctions, with the exception of intron 37, follow the GT-AG rule (16) ( Table 1) . Intron 37 possesses an AT donor site, as verified by sequencing the corresponding exon boundary in unaffected individuals. Several cases of non-consensus intron-exon boundaries have been described (17) , although the splicing mechanism involved in such cases has not been studied. In order to determine the intron sizes, PCR amplification of each intron was attempted on λ phages using primers derived from the sequences of the flanking exons. Introns 2-47 were found to range in size between 100 bp and 8 kb ( Table 1) . The distance between exon 1 and exon 2 was estimated by Southern blot analysis to be a maximum of 23 kb. Therefore, the size of the gene from the first exon to the polyadenylation site does not exceed 90 kb.
The intron-exon structure of the human myosin VIIA gene represents the first characterized mammalian unconventional myosin gene structure. The only previously reported unconventional myosin gene structure is that of Acanthamoeba castellanii 'High Molecular Weight Myosin I' (HMWM1) (18) . Alignment of the sequences encoding the head domains of human myosin VIIA (exons 1-17) and amoeba HMWM1 (exons 1-9) reveals the conservation of two of the exon boundaries; the 5′ limits of HMWM1 exons 3 and 7 correspond to those of myosin VIIA exons 4 and 11, respectively. These boundaries are likely to represent those of ancestral exons. The present data will certainly contribute to further studies on the evolution of the unconventional myosin gene family, of which the number of members identified is currently increasing (19) .
Mutations in USH1B patients
Given the lack of myosin VIIA expression in lymphocytes and fibroblasts (10), the search for mutations was conducted through the analysis of genomic DNA. Six affected families in which segregation analysis was consistent with the involvement of the USH1B gene in the disease, and another patient (individual 8) already having been shown to carry one defective myosin VIIA allele (20) were explored in the present study. Most of the exons were amplified using intronic flanking primers situated at a distance of at least 30 bp from the corresponding intron-exon boundary (Table 2) . However, for exons 23, 28 and 37, a more effective amplification was obtained using primers derived from the next exons. PCR products were sequenced (see Materials and Methods).
A total of eight polymorphisms, six silent and two leading to amino acid substitutions, were detected ( Table 3 ). The 47C→T transition and the 4996T→A transversion leading to amino acid substitutions were also present in nine and 22 out of 50 unaffected control individuals, respectively, of whom three and 18 individuals, respectively, were homozygous for the polymorphism.
The analysis of myosin VIIA exons 4-8 in eight families affected by USH1 had previously led to the characterization of both defective alleles in family 1, and of one defective allele in families 2 and 3 (10) and in individual 8 (20) . Four additional mutations were identified in the present study, following the analysis of the entire myosin VIIA coding region in families 2-7 and in individual 8 (Table 4 and Fig. 1 ). In the single patient from family 2 for whom a nonsense mutation inherited from his mother had previously been identified in exon 6, a heterozygous 3750+2T→A transition was identified within the donor splice site of intron 28; this mutation was also present in his father. In the two patients from family 4, a 6409G→A transition in exon 46, leading to Gly2137Glu substitution, was found on both alleles. Both parents were heterozygous for the mutation. This transition was absent in 50 unaffected control individuals, and therefore is likely to be responsible for the disease. The implicated glycine residue is located within the ERM domain and is conserved in band 4.1 protein superfamily members such as merlin (Gly240, GenBank accession number P26039) and moesin (Gly223, GenBank accession number P26038). This G2137E substitution may impair the binding of the myosin VIIA ERM domain to its putative membrane ligand. In the two affected patients from family 5, a heterozygous 2863G→A transition leading to Gly955Ser substitution was identified in exon 22. This transition was present in the mother and was absent in 50 unaffected control individuals, and thus is likely to be responsible for the disease. The implicated glycine residue lies 20 amino acids after the alpha-helical domain which would be involved in the predicted dimerization of myosin VIIA (10); this substitution may thus interfere with the dimerization process. Finally, in individual 8, a heterozygous 73G→A transition leading to Gly25Arg substitution was detected in exon 2, introducing a positive charge into the protein. This transition was absent in 50 unaffected control individuals and therefore is likely to be responsible for the disease.
The determination of the myosin VIIA gene structure has allowed a screening for mutations in the coding region and splice sites of the myosin VIIA gene in eight unrelated patients affected by Usher syndrome type I. A total of 10 mutated alleles were characterized out of the 16 expected. The mutations consist of two different nonsense mutations, three missense mutations, two Table 1 . Exon-intron organization of the human myosin VIIA gene a Uppercase letters denote the positions matching the consensus splice junction sequences (16) . Bold capitals indicate splice sites. Y, pyrimidine; R, purine; N, undefined small deletions (one of them present in two different families), and one splice site mutation (present on both alleles). Of the six uncharacterized mutated alleles only two are from patients with one mutation already identified. It is important to note that in the case of two different defective alleles segregating in a family, the PCR-based screening method used here would not detect a heterozygous deletion not comprised within the interval defined by each set of primers used for exon amplification. For families 6 and 7, in which no mutation has been found, the involvement of the USH1B locus in the disease can be questioned. In family 6, possible linkage to the USH1B locus was established with only one affected and one unaffected child. While the USH1A, USH1C and USH1E loci could be excluded in this family, the possible involvement of another USH1 locus cannot be ruled out. In family 7, a consanguineous family, linkage to the USH1B locus was established through the analysis of two affected and three unaffected children. The involvement of a defective myosin VIIA gene in this family is therefore very likely. The remaining undetected mutations in the myosin VIIA gene might be located within the uncharacterized promoter region, within the a Exons 9 and 10, 19 and 20, 31 and 32, 32 and 33 were amplified by pair. Exons 19-20: PCR was performed with the addition of 10% DMSO. b PCR primers derived from the sequences of the neighbouring exons. The sequencing intronic primers were the following: 23F 5′-TTGAACTTCTGGGCTCAGG-3′; 23R 5′-CACAAGCAGCAGAGTC-CA-3′; 28F 5′-AAAGCAACCTGGCCTGGAG-3′; 28R 5′-GAGGCACTCGAGTGCACTG-3′; 37F 5′-TCTCACAACCTGGGGGTTT-3′; 37R 5′-CCTCAGGAGGAAGGCAGTG-3′; c Long-Range PCR. Despite the diversity of mutations responsible for USH1B, the possibility should now be considered of a sequence-based prenatal diagnosis in some of the families affected by this very severe form of Usher syndrome. The present study also opens the possibility to test whether or not DFNB2, the non-syndromic form of deafness assigned to the USH1B chromosomal region (21) , also results from a defect in the myosin VIIA gene.
MATERIALS AND METHODS
Designing oligonucleotides in the intronic sequences flanking the myosin VIIA exons
The nine previously described recombinant λ phages covering the coding portion of the myosin VIIA gene as well as the complete 3′ and part of the 5′ untranslated regions (10) were sequenced using primers derived from the myosin VIIA cDNA sequence in order to determine the exon-intron boundaries and the intronic sequences flanking each exon for a minimum of 150 bp. These sequences were used to design oligonucleotides for PCR amplification of the corresponding exons using the Oligo 4.0 Software ( Table 2) . 
DNA sequencing
Sequencing of double-stranded DNA templates was performed by the dideoxy chain terminator method (22) using fluorescent dideoxynucleotides as previously described (10) . Sequences were analyzed on Applied Biosystems (ABI373 or ABI377) DNA sequencers. Most exons amplified individually were sequenced using the same oligonucleotides used for the PCR amplification. Some exons were amplified either in pairs (exons 9-10, 19-20, 31-32 and 32-33) or using exonic primers (exons 23, 28 and 37) (see Table 2 ).
